Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 11/20 | 0.80 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.48 |
| ▸ | ALPG | P10696 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.47 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6043919 | 0.89 | HCAR3 (1.00) | HCAR3THRBPTGER4 | |
| SCHEMBL6044299 | 0.88 | HCAR3 (0.67) | HCAR3PLA2G4AMAPT | |
| SCHEMBL6044721 | 0.82 | HCAR3 (0.66) | HCAR3THRBPTGER4CSNK2A2CSNK2A1 | |
| SCHEMBL6044668 | 0.78 | HCAR3 (0.77) | HCAR3PLA2G4AMAPT | |
| SCHEMBL6044486 | 0.78 | HCAR3 (1.00) | HCAR3PLA2G4AMAPTPTGER4 | |
| SCHEMBL6044508 | 0.76 | HCAR3 (1.00) | HCAR3PLA2G4A | |
| SCHEMBL6685414 | 0.76 | HCAR3 (0.85) | HCAR3PLA2G4AMAPTPTGER4 | |
| SCHEMBL6044303 | 0.75 | HCAR3 (1.00) | HCAR3 | |
| SCHEMBL28544878 | 0.74 | HCAR3 (0.67) | HCAR3PLA2G4ASMN1; SMN2MAPT | |
| SCHEMBL6044071 | 0.74 | HCAR3 (1.00) | HCAR3PLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | GCGR, GPR119, HMGCR | HCAR3 85/4885THRB 1744/4885PLA2G4A 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.